RBC Capital notes that Gilead (GILD) shared a statement that its weekly oral HIV treatment program 1720/4182 combo has been placed on a clinical hold following decreases in CD4 and lymphocyte counts ...

The Food and Drug Administration has placed a clinical hold on Gilead’s (GILD) HIV treatment trials of GS-1720 and/or GS-4182 ...